SRR650184
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.630
- E2F_TARGETS+0.550
- ANGIOGENESIS+0.530
- G2M_CHECKPOINT+0.520
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.500
- INTERFERON_GAMMA_RESPONSE+0.480
- INFLAMMATORY_RESPONSE+0.450
- IL6_JAK_STAT3_SIGNALING+0.430
- APICAL_JUNCTION+0.340
- MITOTIC_SPINDLE+0.340
Top 10 suppressed
- BILE_ACID_METABOLISM-0.450
- FATTY_ACID_METABOLISM-0.440
- OXIDATIVE_PHOSPHORYLATION-0.420
- PEROXISOME-0.360
- ADIPOGENESIS-0.330
- XENOBIOTIC_METABOLISM-0.310
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.300
- CHOLESTEROL_HOMEOSTASIS-0.210
- ANDROGEN_RESPONSE-0.190
- HEME_METABOLISM-0.140
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR650185 | — | — | 0.996 |
| 2 | SRR934821 | — | — | 0.894 |
| 3 | TCGA-FD-A3B7-01A-31R-A20F-07 | — | — | 0.883 |
| 4 | TCGA-55-A493-01A-11R-A24H-07 | — | cohortA1 | 0.879 |
| 5 | TCGA-FD-A3B3-01A-12R-A206-07 | — | — | 0.870 |
| 6 | TCGA-85-A511-01A-21R-A262-07 | — | cohortSQ1 | 0.867 |
| 7 | TCGA-DK-A3WX-01A-22R-A22U-07 | — | — | 0.850 |
| 8 | TCGA-FD-A62S-01A-11R-A30C-07 | — | — | 0.850 |
| 9 | SRR650191 | — | — | 0.848 |
| 10 | TCGA-GC-A3YS-01A-11R-A23N-07 | — | — | 0.847 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.630 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.550 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.530 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.520 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.500 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.480 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.450 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.430 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.340 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.340 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.330 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.330 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.310 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.300 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.280 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.260 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.250 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.250 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.220 | Inavolisib | — uncovered |
| COMPLEMENT | 0.210 | Inavolisib | — uncovered |